TORONTO, Aug. 15, 2018 /PRNewswire/ - GeneNews Limited (TSX: GEN), an innovator in the liquid biopsy space, today announced a partnership with Pittsburgh-based, LifeX™, a strategic engine for developing and nurturing cutting-edge, life-saving health solutions and bringing these innovations to market.
LifeX™ was founded by CEO, Dietrich Stephan, PhD, a renowned human geneticist and entrepreneur recognized for his early leadership in the field of Precision Medicine. The LifeX™ mission is to deliver new solutions to tackle prevalent and intractable global diseases.
GeneNews, which provides innovative solutions for early cancer detection, will work together with LifeX™to develop strategies for incorporating several proprietary, early cancer diagnostics into healthcare settings to improve patient compliance with cancer screening, as well as to bridge the diagnostic gaps in current screening procedures.
Early detection of cancer is known to improve outcomes. Few, if any, technologies can detect tumors at an early stage, hampering the ability to have a transformational population-wide impact driven by broad-based screening. GeneNews has several tests that have been developed and tested in many thousands of patients and proven to detect cancer at an early stage using a simple blood test, termed a "liquid biopsy."
"Most of today's research initiatives are focused on developing treatment for late-stage cancers versus finding it in the early stages, when it is most curable and survival rates are highest," says GeneNews' CEO, James R Howard-Tripp. "To really make a difference in improving and saving lives, our solutions start at the beginning of disease not at the end."
"We look forward to bringing GeneNews' solutions to the marketplace to make a tangible difference in global health by enabling cures when cancer is most treatable,"says Dr. Stephan. "Other liquid biopsy companies are focused on monitoring response to chemotherapy or detecting recurrence of tumors after initial treatment. GeneNews, one of the pioneers of the liquid biopsy, has developed the 'holy-grail' – a suite of tests that have the correct sensitivity and specificity to detect cancer early and perform correctly as a screening tool at the population level."
These tests are part of a platform, known as Aristotle™, which is based on GeneNew's proprietary mRNA Sentinel Principle technology that can generate highly discriminative multi-gene panels for many diseases. GeneNews is currently working on a panel for the simultaneous monitoring of ten cancers from a single blood sample.
Thomas Stewart, President & CEO of JTS Health Partners was instrumental in bringing this collaboration together. "In my capacity as strategic advisor to this partnership, I'm excited about the collaboration's impact and the opportunity to remain actively engaged in the growth and success of the venture. LifeX™, GeneNews and JTS Health Partners bring unique synergies that are patient oriented and client centric. The innovative capabilities of our collective organizations will advance value and quality-based reimbursement models that drive enterprise cost reduction for health systems and large employers through early cancer intervention."
LifeX™ develops first-in-class solutions to alleviate suffering and death from horrific, prevalent and intractable diseases. The LifeX™ team partners with innovator-entrepreneurs to unlock the potential of their technologies and deliver them to patients and their physicians across the globe. LifeX™ was founded by Dr. Dietrich Stephan, with founding support from the University of Pittsburgh and the Henry L. Hillman Foundations. https://www.lifexventures.com
JTS Health Partners
Formed in 2002 as a technology professional services company, JTS has evolved to become a leading healthcare management consulting and professional services firm dedicated to meeting the needs of the nation's many top healthcare organizations in both the private and public sector. JTS's healthcare management consulting and services portfolio is focused on enterprise advisory planning, health information management, information technology, financial and revenue cycle management. The company also works on operational performance improvement initiatives for hospitals and physicians, inclusive of data analytics, and offers other professional services that include staff augmentation for the acute and physician settings. More information on JTS can be found at www.jtshealthpartners.com.
This press release contains forward-looking statements identified by words such as "expects", "will", "may" and similar expressions, which reflect the Company's current expectations regarding future events, including with respect to the receipt of shareholder approval. The forward-looking statements involve risks and uncertainties that could cause actual events to differ materially from those projected herein including the state of the equity capital markets, the receipt of required approvals, the future financial and operating performance of the Company and its subsidiaries, requirements for and availability of additional capital and the general business and political environment including in the healthcare sector. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.